STOCK TITAN

Myomo Stock Price, News & Analysis

MYO NYSE

Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.

Myomo Inc. (MYO) is a leader in developing wearable medical robotics that restore mobility for individuals with neuromuscular disorders. This page serves as the definitive source for official company announcements, providing stakeholders with timely updates on innovations shaping the orthotics industry.

Access curated press releases covering FDA milestones, product launches, and financial performance reports. Investors will find earnings disclosures and partnership announcements, while healthcare professionals can track clinical trial outcomes and insurance coverage expansions.

Our repository includes updates on Myomo’s myoelectric brace development, research collaborations with medical institutions, and regulatory progress across global markets. All content is sourced directly from company filings and verified channels to ensure accuracy.

Bookmark this page to monitor how MYO’s neuro-robotic solutions are advancing patient care while creating long-term value in the medical technology sector. Check regularly for developments impacting both clinical and investment communities.

Rhea-AI Summary

Myomo, Inc. (NYSE American: MYO) announced an amended joint venture agreement with Beijing Ryzur Medical Investment and Wuxi Chinaleaf Rehabilitation Fund. Myomo retains a 19.9% stake in the venture, while Ryzur holds 65.1%. An upfront license fee of $2.7 million will be paid for technology and trademark licensing, with $0.2 million due within 30 days. $10.75 million is guaranteed over 10 years. Operations in China will commence upon full payment of the license fee expected by March 31, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
-
Rhea-AI Summary

Myomo (NYSE American: MYO) reported record financial results for Q3 2021, achieving $4.4 million in revenue, a 128% increase year-over-year, and 159% year-to-date. Gross margin improved to 75%, up 1,900 basis points. The backlog rose to a record 177 units. However, the company faces challenges including temporary labor shortages impacting deliveries. The net loss for Q3 was $2.1 million, or $0.36 per share. Despite strong revenue growth, forecasting for Q4 is difficult due to these constraints.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
-
Rhea-AI Summary

Myomo, Inc. (NYSE American: MYO) will announce its financial results for the three and nine months ended September 30, 2021 on November 10, 2021, after the market closes. The company will hold a conference call on the same day at 4:30 p.m. ET, featuring remarks from CEO Paul R. Gudonis and CFO David Henry. Participants can pre-register for the call or join through provided dial-in information. Myomo specializes in wearable medical robotics aimed at aiding patients with upper-limb paralysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences earnings
Rhea-AI Summary

Myomo, Inc. (NYSE American: MYO) has announced agreements with warrant holders to exercise 1,015,798 shares at $5.00 each, generating approximately $5.1 million in gross proceeds. This exercise is crucial for increasing capital for the wearable medical robotics company, which aims to enhance functionality for those with neurological disorders and upper-limb paralysis. The company's MyoPro product line helps restore mobility to patients, enabling them to perform daily activities and potentially return to work.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
none
-
Rhea-AI Summary

Myomo, Inc. (NYSE American:MYO) announced participation in the Fall Harvest - Best Ideas From the Buy-Side conference from October 5-8, 2021. CEO Paul Gudonis and CFO David Henry will present on October 5 at 1:00 p.m. ET, with live webcasting available. One-on-one meetings can be scheduled during the conference. Myomo specializes in wearable medical robotics, focusing on assisting those with neurological disorders and upper-limb paralysis through its MyoPro product line.

For more details, visit www.myomo.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
conferences
-
Rhea-AI Summary

Myomo, Inc. (NYSE American: MYO) has secured patents for its advanced powered orthotic device in China and Hong Kong. The patents, effective until June 2036, will be licensed to a joint venture in China created with Beijing Ryzur Medical Investment Co., Ltd.. This venture aims to introduce Myomo's technology to the extensive Chinese market, which has approximately 14 million individuals with upper-arm paralysis. The CEO expressed optimism about becoming a standard care solution for these patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
none
Rhea-AI Summary

Myomo, Inc. (NYSE American:MYO), a company specializing in wearable medical robotics for neurological disorders and upper-limb paralysis, announced participation in three investment conferences in September 2021. These include the Colliers Institutional Investor Conference on September 9, the H.C. Wainwright Global Investment Conference from September 13-15, and the Oppenheimer Fall Healthcare Summit from September 20-23. Myomo's MyoPro device is the only one that restores arm function using the patient's own EMG signals, enabling independence for users.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
-
Rhea-AI Summary

Myomo, a wearable medical robotics company, reported significant financial growth for Q2 2021. Revenue reached $3.1 million, a 262% increase year-over-year, with 80 units sold, up 233%. Gross margin improved to 71%, up from 51% a year ago. Operating loss narrowed to $2.6 million from $2.8 million year-over-year. The backlog rose by 36% to 160 units. Management is optimistic for continued growth in Q3, driven by direct-to-patient marketing and expanding insurance coverage for MyoPro devices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.31%
Tags
-
Rhea-AI Summary

Myomo, Inc. (NYSE American: MYO) will report its financial results for the three and six months ended June 30, 2021 on August 9, 2021, after market close. A conference call will follow at 4:30 p.m. ET with remarks from CEO Paul R. Gudonis and CFO David Henry. Participants are encouraged to pre-register for immediate access. Myomo specializes in wearable medical robotics aimed at improving upper limb function in patients with neurological disorders and paralysis, featuring the MyoPro product line that utilizes EMG sensors for functionality restoration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences earnings
News
Rhea-AI Summary

Myomo, Inc. (NYSE American: MYO) announced its accreditation by the Healthcare Quality Association on Accreditation (HQAA), confirming compliance with the Social Security Act requirements. This accreditation follows the Company’s authorization as a Medicare Provider by the Centers for Medicare & Medicaid Services (CMS). CEO Paul R. Gudonis highlighted that while reimbursement for MyoPro orthosis is approved on a case-by-case basis, broader coverage could enhance service for beneficiaries suffering from upper-limb paralysis. However, he emphasized that coverage terms from CMS are still pending.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none

FAQ

What is the current stock price of Myomo (MYO)?

The current stock price of Myomo (MYO) is $2.03 as of July 3, 2025.

What is the market cap of Myomo (MYO)?

The market cap of Myomo (MYO) is approximately 79.9M.
Myomo

NYSE:MYO

MYO Rankings

MYO Stock Data

79.87M
31.56M
5.14%
59.2%
2.28%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BOSTON